The Journal of Urology
Volume 184, Issue 2 , Pages 512-518 , August 2010

Stage IV Prostate Cancer: Survival Differences in Clinical T4, Nodal and Metastatic Disease

  • Wayland Hsiao

      Affiliations

    • Department of Urology, Emory University School of Medicine, Atlanta, Georgia
    • Nothing to disclose.
    • ,
  • Kelvin A. Moses

      Affiliations

    • Department of Urology, Emory University School of Medicine, Atlanta, Georgia
    • Nothing to disclose.
    • ,
  • Michael Goodman

      Affiliations

    • Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, Georgia
    • Supported by the Atlanta Clinical and Translational Science Institute.
    • ,
  • Ashesh B. Jani

      Affiliations

    • Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia
    • Winship Cancer Institute, Emory University, Atlanta, Georgia
    • Nothing to disclose.
    • ,
  • Peter J. Rossi

      Affiliations

    • Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia
    • Winship Cancer Institute, Emory University, Atlanta, Georgia
    • Nothing to disclose.
    • ,
  • Viraj A. Master

      Affiliations

    • Department of Urology, Emory University School of Medicine, Atlanta, Georgia
    • Winship Cancer Institute, Emory University, Atlanta, Georgia
    • Nothing to disclose.
    • Corresponding Author InformationCorrespondence: Department of Urology, Emory University School of Medicine, 1365 Clifton Rd. NE, Building B, Atlanta, Georgia 30322 (telephone: 404-778-5881)

Received 20 December 2009

References 

  1. Cooperberg MR, Park S, Carroll PR. Prostate cancer 2004: insights from national disease registries. Oncology (Williston Park). 2004;18:1239
  2. Ahaghotu C, Baffoe-Bonnie A, Kittles R, et al. Clinical characteristics of African-American men with hereditary prostate cancer: the AAHPC Study. Prostate Cancer Prostatic Dis. 2004;7:165
  3. Scales CD, Moul JW, Curtis LH, et al. Prostate cancer in the Baby Boomer generation: results from CaPSURE. Urology. 2007;70:1162
  4. Leijte JA, Gallee M, Antonini N, et al. Evaluation of current TNM classification of penile carcinoma. J Urol. 2008;180:933
  5. Chun FK, Briganti A, Lebeau T, et al. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. Eur Urol. 2006;49:273
  6. Hutterer GC, Karakiewicz PI. Can the AJCC staging system risk-stratify patients with localized prostate cancer?. Nat Clin Pract Urol. 2007;4:482
  7. May F, Hartung R, Breul J. The ability of the American Joint Committee on Cancer staging system to predict progression-free survival after radical prostatectomy. BJU Int. 2001;88:702
  8. Roach M, Weinberg V, Sandler H, et al. Staging for prostate cancer: time to incorporate pretreatment prostate-specific antigen and Gleason score?. Cancer. 2007;109:213
  9. Taylor SH, Merriman KW, Spiess PE, et al. Inadequacies of the current American Joint Committee on Cancer staging system for prostate cancer. Cancer. 2006;106:559
  10. Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer (A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy). Eur Urol. 2009;55:261
  11. Guinan P, Stewart AK, Fremgen AM, et al. Patterns of care for metastatic carcinoma of the prostate gland: results of the American College of Surgeons' patient care evaluation study. Prostate Cancer Prostatic Dis. 1998;1:315
  12. Resnick MI, Grayhack JT. Treatment of stage IV carcinoma of the prostate. Urol Clin North Am. 1975;2:141
  13. Johnstone PA, Ward KC, Goodman M, et al. Radical prostatectomy for clinical T4 prostate cancer. Cancer. 2006;106:2603
  14. Van Poppel H, Joniau S. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. Eur Urol. 2008;53:253
  15. Boorjian SA, Thompson RH, Siddiqui S, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol. 2007;178:864
  16. Cheng CW, Bergstralh EJ, Zincke H. Stage D1 prostate cancer (A nonrandomized comparison of conservative treatment options versus radical prostatectomy). Cancer. 1993;71:996
  17. Gjertson CK, Asher KP, Sclar JD, et al. Local control and long-term disease-free survival for stage D1 (T2-T4N1-N2M0) prostate cancer after radical prostatectomy in the PSA era. Urology. 2007;70:723
  18. Kroepfl D, Loewen H, Roggenbuck U, et al. Disease progression and survival in patients with prostate carcinoma and positive lymph nodes after radical retropubic prostatectomy. BJU Int. 2006;97:985
  19. Powell IJ, Tangen CM, Miller GJ, et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, Phase II Southwest Oncology Group Study 9109. J Urol. 2002;168:2016
  20. Shuch B, Mikhail M, Satagopan J, et al. Racial disparity of epidermal growth factor receptor expression in prostate cancer. J Clin Oncol. 2004;22:4725

 Editor's Note: This article is the third of 5 published in this issue for which category 1 CME credits can be earned. Instructions for obtaining credits are given with the questions on pages 800 and 811.

PII: S0022-5347(10)03295-7

doi: 10.1016/j.juro.2010.04.010

The Journal of Urology
Volume 184, Issue 2 , Pages 512-518 , August 2010

Article Tools

* Image Usage & Resolution